Amicus Therapeutics Take Pride And Shows Passion In Inventive New Therapies

Amicus Therapeutics is dedicated to the field of biotechnology. Their global operations have given them the ability to use advanced therapies in the treatment of diseases that have caused devastation. They are constantly filling their pipeline with new treatments so genetic diseases can eventually be cured. Their passion to the field combined with hard work has already begun to make a difference.

 

Amicus Therapeutics has a product they call migalastat which is currently their top candidate. The product is based on an individuals genetics and designed for the treatment of Fabry disease. An additional product called SD-101 is in the final stages of development and may be the first product of its class to arrive on the market. The product is designed to combat Epidermolysis Bullosa. This condition is a rare disorder of the connective tissues and it is genetic. Amicus Therapeutics uses a combination of therapies to formulate products for numerous diseases.

 

The year was 2005 when the Amicus employees gathered with the intention of creating a statement that would encompass their critical values. This statement would always be a reminder of why they were there and what they wanted to accomplish. The beliefs, commitment, and passions of these individuals are the reflection of Amicus. Their standards are incredibly high, their natures bold, and their work driven.

 

Amicus believes in fighting to find the therapies necessary to combat rare diseases. They believe the people suffering from these diseases deserve nothing less than therapies of the highest possible quality and will always give their full support to these individuals and their families (WeeklyOpinion). The individuals who are the heart of Amicus are filled with passion about their careers and believe innovation must be encouraged and embraced. They take their duty to advance their technologies very seriously and take ideas as far as they can go as quickly as they can get there. The risks they take are intelligent and they work incredibly hard. Amicus is not afraid of asking the difficult questions and will not let themselves be restricted by outdated thinking. Amicus has learned from the mistakes they have made and takes pride in thinking differently.

 

More at http://www.marketwatch.com/investing/stock/fold

 

Leave a Reply

Your email address will not be published. Required fields are marked *